ANIP · NASDAQ · STOCK
ANI Pharmaceuticals, Inc.
$74.51
52W $70.15 – $99.50
60/100
$1.69B
15.4
0.46
Is ANIP Bullish or Bearish?
Mixed.
Innellis AI committee rates ANI Pharmaceuticals, Inc. (ANIP) Insufficient Data with a composite score of 60/100
, based on 3 analysts with 67% agreement.
Last updated August 11, 2026.
What Would Change This View
No threshold can be published for ANIP. The committee has not produced a scored recommendation, so there is no line for it to cross. Innellis does not infer one.
Executive Summary
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull & Bear Case
Bull Case
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Price trading below the lower Bollinger Band -- stretched to the downside — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
60/100
Agreement
67%
Analysts
3
Conviction
Low Data
Sector Rank
Top 47%
of 192 Healthcare peers
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
neutral
54
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
31.0
Neutral
MACD Histogram
-0.414
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$74.23
Resistance
$86.67
Bollinger %B
-0.08
Below Lower Band
Price vs Moving Averages
EMA 9
$78.18
Below
EMA 21
$79.38
Below
EMA 50
$80.15
Below
EMA 200
$79.55
Below
Fundamental Analysis
Valuation
94
Profitability
70
Financial Health
99
Cash Flow
70
Valuation
P/E Ratio
15.4×
P/B Ratio
2.64×
PEG Ratio
0.01
Dividend Yield
0.00%
52W High
$99.50
52W Low
$70.15
Quality & Growth
ROE
1448.7%
ROA
543.9%
Gross Margin
6523.0%
Operating Margin
1534.9%
Revenue Growth YoY
—
Debt / Equity
0.55
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of 15.4 (inexpensive relative to a 15-40x range); Price-to-book of 2.6x; PEG ratio of 0.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 14.5%; Return on assets of 5.4%; Net margin of 10.8%; Gross margin of 65.2%; Current ratio of 2.91 (healthy short-term liquidity); Debt-to-equity of 0.55; Free cash flow per share is positive (7.54); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full ANIP Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →